Top Markets
Coin of the day
Achilles Therapeutics plc Achilles Therapeutics plc

Achilles Therapeutics plc

ACHL
Rank in Stocks #24575
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused... Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Share Price
$1.48
Last synced: 2025-03-24
Market Cap
$59.05M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
GB
Trade Achilles Therapeutics plc (ACHL)

Category

Earnings for Achilles Therapeutics plc (ACHL)
Earnings in 2026 TTM: 0
According to Achilles Therapeutics plc latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Achilles Therapeutics plc from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$1.61B -
AU
- -
CH